JP Morgan Maintains Overweight on Maze Therapeutics, Raises Price Target to $58

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Maze Therapeutics (NASDAQ: MAZE) and increased the price target from $52 to $58.